Vitiligo development in a patient with psoriasis vulgaris treated with ixekizumab

Eker, Hediye; İslamoğlu, Zeynep Gizem Kaya; Demirbaş, Abdullah

doi:10.1111/dth.15314

Cited by 3 publications

(1 citation statement)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the dermatological aspect, adverse events such as paradoxical psoriasis and atopic-like eczema have been reported. Rarely, the development of neutrophilic dermatoses, hypersensitivity reactions, lichenoid eruptions, vasculopathies, granulomatous diseases, lupus-like reactions, hair disorders, and vitiligo have also been reported in association with the use of ixekizumab [ 7 , 8 , 9 ]. Close monitoring and awareness of these potential adverse events are necessary during treatment with ixekizumab.…”

Section: Introductionmentioning

confidence: 99%

Risk Factors of Ixekizumab-Induced Injection Site Reactions in Patients with Psoriatic Diseases: Report from a Single Medical Center

Chiu

Tsai

2023

Biomedicines

View full text Add to dashboard Cite

Ixekizumab (Taltz®) is a humanized anti-IL-17A monoclonal antibody approved for the treatment of various inflammatory diseases including psoriasis and psoriatic arthritis. Despite the favorable efficacy and safety, ixekizumab is also known for its high incidence of injection site reactions (ISRs), ranging from 6% to 55% in different studies according to different definitions and studied population. However, specific risk factors for ixekizumab-induced injection site reactions in patients with psoriatic diseases had not been well studied. In this retrospective study, we found that overweight or obesity might be a protective predictor for the occurrence of ixekizumab-induced ISRs in patients with psoriatic disease. Meanwhile, having a positive family history of psoriasis might be a potential risk factor. Last but not least, patients with diarrhea following ixekizumab injection were associated with a higher risk of developing ISRs. Future high-quality studies with larger samples are warranted to verify the relationship.

show abstract

Section: Introductionmentioning

confidence: 99%

Risk Factors of Ixekizumab-Induced Injection Site Reactions in Patients with Psoriatic Diseases: Report from a Single Medical Center

Chiu

Tsai

2023

Biomedicines

View full text Add to dashboard Cite

show abstract

Biologic drugs induced vitiligo: case reports and review of literature

Shao,

Chen,

Pan

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

Biological drugs are extensively used to treat various inflammatory diseases, including psoriasis, atopic dermatitis (AD), and rheumatoid arthritis. While generally effective and safe, these therapies have been increasingly associated with secondary development of vitiligo, especially with anti-TNF α and anti-IL17 drugs. Dupilumab, an IL-4 receptor alpha antagonist used in moderate to severe AD, rarely induces vitiligo. This study reports two cases of new-onset vitiligo following dupilumab treatment for AD. The first case involves an 80-year-old male who developed vitiligo patches appeared on the chest, back, and lower limbs after 2 months of dupilumab therapy. Despite discontinuation of dupilumab, the vitiligo did not regress. The second case describes a 14-year-old female who experienced depigmentation on her forehead one month into dupilumab treatment, with partial improvement of vitiligo lesions over time despite continued therapy. This phenomenon may be due to dupilumab blocking type 2 inflammation, disrupting normal skin homeostasis, and exacerbating type 1 inflammation. These cases, supplemented with a literature review, highlight the potential for biologic drug-induced vitiligo and underscore the need for awareness of such adverse events in clinical practice. The mechanisms underlying this phenomenon likely involve disruption of the Th1/Th2/Th17 cytokine balance, suggesting that targeted therapies may inadvertently exacerbate type 1 inflammation, leading to vitiligo. With the rising use of biologics, clinicians should carefully consider the risk of vitiligo when prescribing these treatments.

show abstract

Role of Cytokines and Chemokines in Vitiligo and Their Therapeutic Implications

Kądziela,

Kutwin,

Karp

et al. 2024

JCM

View full text Add to dashboard Cite

Vitiligo is a persistent autoimmune disease characterized by progressive depigmentation of the skin caused by the selective destruction of melanocytes. Although its etiopathogenesis remains unclear, multiple factors are involved in the development of this disease, from genetic and metabolic factors to cellular oxidative stress, melanocyte adhesion defects, and innate and adaptive immunity. This review presents a comprehensive summary of the existing knowledge on the role of different cellular mechanisms, including cytokines and chemokines interactions, in the pathogenesis of vitiligo. Although there is no definitive cure for vitiligo, notable progress has been made, and several treatments have shown favorable results. A thorough understanding of the basis of the disease uncovers promising drug targets for future research, providing clinical researchers with valuable insights for developing improved treatment options.

show abstract

Vitiligo development in a patient with psoriasis vulgaris treated with ixekizumab

Cited by 3 publications

References 15 publications

Risk Factors of Ixekizumab-Induced Injection Site Reactions in Patients with Psoriatic Diseases: Report from a Single Medical Center

Risk Factors of Ixekizumab-Induced Injection Site Reactions in Patients with Psoriatic Diseases: Report from a Single Medical Center

Biologic drugs induced vitiligo: case reports and review of literature

Role of Cytokines and Chemokines in Vitiligo and Their Therapeutic Implications

Contact Info

Product

Resources

About